雷美替胺、苏沃雷生与莱博雷生预防住院患者谵妄的疗效:系统评价与Meta分析
该系统评价与Meta分析纳入24项研究共4489例住院成人患者,其中1752例(39%)接受雷美替胺、苏沃雷生或莱博雷生。随机试验(RR 0.60;95%CI 0.38-0.97;低确定性)和观察性研究(RR 0.54;95%CI 0.43-0.68;低确定性)均显示谵妄患病率显著降低。按单个药物进行的探索性分析未发现可信的亚组效应(交互作用P>0.1)。通气天数、死亡率、住院或ICU停留时间均无显著影响(极低确定性)。作者结论认为这些药物与谵妄患病率相对风险降低40%-46%相关,但证据确定性低,各药物比较疗效的结论受限,需进一步高质量前瞻性试验确认。
要点
- 随机试验汇总显示,睡眠-觉醒调节药物与谵妄患病率降低相关(RR 0.60;95%CI 0.38-0.97;低确定性)。
- 观察性研究汇总显示,同类药物与谵妄患病率降低相关(RR 0.54;95%CI 0.43-0.68;低确定性)。
- 按单个药物(雷美替胺、苏沃雷生、莱博雷生)的探索性分析未发现可信亚组效应(交互作用P>0.1),药物特异性结论需谨慎解读。
- 通气天数、死亡率、住院或ICU停留时间均无显著影响(极低确定性)。
- 作者结论:睡眠-觉醒调节药物与谵妄患病率相对风险降低40%-46%相关,但证据确定性低,需进一步高质量前瞻性试验确认。
适用人群与场景
- 住院成人患者,包括老年人和ICU人群。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入随机对照试验或观察性研究,共24项研究、4489例患者,其中1752例(39%)接受雷美替胺、苏沃雷生或莱博雷生。
- 主要终点:随机试验中谵妄患病率汇总RR 0.60(95%CI 0.38-0.97;低确定性);观察性研究中汇总RR 0.54(95%CI 0.43-0.68;低确定性)。
- 探索性分析:按单个药物分析未发现可信亚组效应(交互作用P>0.1),药物特异性发现需谨慎解读。
- 关键次要终点:通气天数、死亡率、住院或ICU停留时间均无显著影响(极低确定性)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,采用GRADE、RoB及ROBINS-I工具评估质量,随机效应模型汇总风险比(RR)及中位差(95%CI)。
- 证据等级:随机试验和观察性研究的谵妄患病率结果均为低确定性;通气天数、死亡率、住院或ICU停留时间结果为极低确定性。
- 局限:按单个药物的探索性分析未发现可信亚组效应(交互作用P>0.1),药物特异性发现需谨慎解读;作者指出需进一步高质量前瞻性试验确认结果并明确特定药物策略在谵妄预防中的作用。
对床旁实践的改变
- 作者认为睡眠-觉醒调节药物与谵妄患病率相对风险降低40%-46%相关,但证据确定性低,需进一步高质量前瞻性试验确认。
- 按单个药物(雷美替胺、苏沃雷生、莱博雷生)的探索性分析未发现可信亚组效应(交互作用P>0.1),药物特异性结论需谨慎解读。
- 通气天数、死亡率、住院或ICU停留时间均无显著影响(极低确定性)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Delirium is a prevalent complication among hospitalized patients, particularly in older adults and ICU populations, and it is associated with poor prognosis. Pharmacologic interventions targeting sleep-wake regulation and neurobiologic pathways, such as orexin receptor antagonists and melatonin receptor agonists, offer promising strategies for delirium prevention. Our objective was to evaluate the preventive efficacy of suvorexant, lemborexant, and ramelteon in reducing delirium prevalence and associated clinical outcomes.
DATA SOURCES: We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials, clinical trial registries, and gray literature databases through November 2024.
STUDY SELECTION: Randomized controlled trials or observational studies involving hospitalized adults assessing the use of suvorexant, lemborexant, or ramelteon for delirium prevention were included.
DATA EXTRACTION: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines, two reviewers extracted data independently. Quality was assessed using the Grading of Recommendations Assessment, Development, and Evaluation; Risk of Bias in Randomized Studies; and Risk of Bias in Nonrandomized Studies-of Interventions tools. Random-effects meta-analysis pooled risk ratios (RRs) and median differences with 95% CIs.
DATA SYNTHESIS: Twenty-four studies involving 4489 patients were analyzed, of whom 1752 (39%) received one of the evaluated pharmacotherapies. Pooled analyses showed a significant reduction in delirium prevalence in both randomized trials (RR, 0.60; 95% CI, 0.38-0.97; low certainty) and observational studies (RR, 0.54; 95% CI, 0.43-0.68; low certainty). Exploratory analyses by individual agent did not identify credible subgroup effects (interaction p > 0.1), and medication-specific findings should be interpreted with caution. No significant effects were observed for ventilator days, mortality, or length of hospital or ICU stay (very low certainty).
CONCLUSIONS: Sleep-wake regulating pharmacologic agents were associated with 40%-46% relative risk reductions in delirium prevalence, based on low-certainty evidence. Although these findings are promising, the absence of credible subgroup effects limits conclusions about the comparative efficacy of individual agents. Further, high-quality, prospective trials are needed to confirm these results and to clarify the role of specific pharmacologic strategies in delirium prevention.
参考来源
- de Oliveira HM, Gallo Ruelas M, Zamora FV, et al. Efficacy of Ramelteon, Suvorexant, and Lemborexant for Delirium Prevention in Hospitalized Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2025. PMID: 40511987. doi:10.1097/CCM.0000000000006737
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。